Evidence map›Paper›PMID 37020837›Full record

ArticleERJ open research2023

Functional imaging in asthma and COPD: design of the NOVELTY ADPro substudy.

Helen Marshall, Jim M Wild, Laurie J Smith, Latife Hardaker, Titti Fihn-Wikander, Hana Müllerová, Rod Hughes

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in ERJ open research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02760329 (A NOVEL Observational longiTudinal studY on Patients With Asthma and/or COPD to Describe Patient Characteristics, Treatment Patterns and the Burden of Illness Over Time and to Identify Phenotypes and Endotypes.), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02760329 completednot on this map

A NOVEL Observational longiTudinal studY on Patients With Asthma and/or COPD to Describe Patient Characteristics, Treatment Patterns and the Burden of Illness Over Time and to Identify Phenotypes and Endotypes.

TypeobservationalSponsorAstraZenecaRan2016 to 2023Enrolled12,255ConditionsAsthma, COPD, Chronic Obstructive Pulmonary DiseaseArmsBlood draw, Urine, Lung function measurements, Fractional Exhaled Nitric Oxide (FENO)
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Deep Learning Reconstruction forMagnetic resonance in medicine · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Helen MarshallPOLARIS, Dept of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.ORCID https://orcid.org/0000-0002-7425-1449
Jim M WildPOLARIS, Dept of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
Laurie J SmithPOLARIS, Dept of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.ORCID https://orcid.org/0000-0002-5769-423X
Latife HardakerPriory Medical Group, York, UK.
Titti Fihn-WikanderEvidence Delivery, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden.
Hana MüllerováRespiratory and Immunology, Medical and Payer Evidence Strategy, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
Rod HughesExternal Scientific Engagement, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
University of Sheffield · GBAstraZeneca (United Kingdom) · GBAstraZeneca (Sweden) · SEThe Priory Hospital · GB

Funding

British Heart Foundation SP/14/6/31350Medical Research Council MR/M008894/1
6 · The paper itself

Abstract

The NOVEL observational longiTudinal studY (NOVELTY; ClinicalTrials.gov identifier NCT02760329) is a global, prospective, observational study of ∼12 000 patients with a diagnosis of asthma and/or COPD. Here, we describe the design of the Advanced Diagnostic Profiling (ADPro) substudy of NOVELTY being conducted in a subset of ∼180 patients recruited from two primary care sites in York, UK. ADPro is employing a combination of novel functional imaging and physiological and metabolic modalities to explore structural and functional changes in the lungs, and their association with different phenotypes and endotypes. Patients participating in the ADPro substudy will attend two visits at the University of Sheffield, UK, 12±2 months apart, at which they will undergo imaging and physiological lung function testing. The primary end-points are the distributions of whole lung functional and morphological measurements assessed with xenon-129 magnetic resonance imaging, including ventilation, gas transfer and airway microstructural indices. Physiological assessments of pulmonary function include spirometry, bronchodilator reversibility, static lung volumes

Identifiers

PMID37020837
PMCPMC10068571
OpenAlexW4318070499

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.